The Life Sciences and Health Care department is a specialized team of lawyers from various fields providing support to pharmaceutical companies, wholesalers, pharmacies and hospitals. We work closely with other departments: tax, labour law and M&A. This enables us to provide clients with comprehensive services both in day-to-day operations and in exceptional events such as transactions or crisis situations.
Pharmaceutical law
Pharmaceutical and medical law, what with the ever-changing regulatory environment, makes it difficult to run an industry enterprise without expert legal support. Our team has extensive experience in pharmaceutical law.
We provide legal advice, attending to obtainment of the requisite permits, representation before relevant authorities and ongoing legal advice.
Services for entities operating in the drug market:
- Wholesale permits, operation of pharmacies, product authorization
- Pharmacovigilance
- Advertising and sales support activities
- Distribution agreements and parallel import issues
- Reimbursement
- Clinical trials
- Protection of intellectual property and counteracting unfair competition
- Representation of clients in litigation and relations with state authorities
Services to medical entities:
- Ongoing legal advice in medical activities
- Relations with the creating entity and the Social Council
- Audit of medical records
- Contracting and subcontracting
- Public procurement
- Activities in proceedings before inspection authorities
- Representation in litigation with the National Health Fund
- Patient rights and patient claims at all stages of proceedings
The basic principle that unites our team is to build relationships based on respect and trust.
We have been advising entrepreneurs for 30 years, so we understand the nature of business and how to properly support it. We focus on efficiency, transparency and partnership.
Experience
Selected projects
- Advised the selling shareholders on the disposal of six Centrum Diagnostyczno-Lecznicze Barska medical facilities to the Unity Care network, backed by the private equity fund Enterprise Investors
- Advised LUX MED on the acquisition of the Mental Path network of seven mental health centres operating in five cities across Poland
- Advised Bioceltix on two equity offerings with a total value of PLN 116 million, comprising a shareholder-led secondary public offering conducted through an accelerated bookbuilding (ABB) process and the issuance of two tranches of new shares funded with proceeds from the ABB
- Advised Bioceltix on the execution of an investment substitution agreement with VTU Engineering Polska for the development of a pharmaceutical manufacturing facility in Wrocław dedicated to veterinary advanced therapy medicinal products (ATMPs)
News
& Insights
12.11.2025
GESSEL advised the LUX MED Group on the acquisition of the Mental Path Group network of psychotherapy centres
GESSEL advised LUX MED, a leading provider of private healthcare services in Poland, on the acquisition of the Mental Path network of psychotherapy ce...
16.01.2026
GESSEL’s dedicated Healthcare M&A team advised on ten sectoral deals in 2025
In 2025, GESSEL successfully advised on ten mergers and acquisitions transactions in the healthcare sector. The mandates covered advisory services on both the sell side ...
15.01.2026
GESSEL advised CenterMed on the acquisition of the Avimed Group
GESSEL advised CenterMed, a Polish network of outpatient clinics and medical facilities operating in the healthcare services market, on the acquisition of the AVIMED Gro...
07.01.2026
GESSEL advised on the sale of Centrum Diagnostyczno Lecznicze Barska to Unity Care
GESSEL advised the selling shareholders on the sale of Centrum Diagnostyczno Lecznicze Barska sp. z o.o., a privately owned healthcare provider, to Unity Care sp. z o.o....
23.10.2025
GESSEL advised on two public offerings of Bioceltix shares with a total value of over PLN 116 million
GESSEL provided comprehensive legal advice to Bioceltix S.A. (the “Company”), a Wrocław-based biotech company, in connection with a public offering of shares conducted t...
10.09.2025
GESSEL advised on execution of an investment substitution agreement for construction of Bioceltix’s production facility
GESSEL advised Bioceltix S.A., an innovative biotechnology company developing biological drugs for animals, on conclusion of an investment substitution agreement for the...
Contact us
